Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa KY1005 in Moderate to Severe Atopic Dermatitis
2018-002299-41Phase 2Completed
- Sponsor
- Kymab
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing KY1005 with Placebo (2 arms). Primary endpoints: Efficacy on signs of atopic dermatitis and Safety - treatment-emergent adverse events. Started Oct 2018; status: completed.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2018-002299-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002299-41.